Vol. 2, Issue 18 | November 10, 2026

Histologic change in compensated cirrhosis after bariatric surgery leads this issue, alongside surgical outcomes after medication failure and retatrutide for knee osteoarthritis. Medicare formulary gaps and new payment rules put the clinical findings in their practice context.

Article of the Week

Sobia Laique, Awwab F. Hammad, Daniela Allende et al. | Annals of Surgery, Nov. 2, 2026 | 10.1097/SLA.0000000000007249

A Cleveland Clinic retrospective study followed 30 patients with biopsy-proven compensated MASH cirrhosis who underwent metabolic bariatric surgery. Median baseline BMI was 43.7 kg/m², and the median interval between biopsies was 6.2 years. Cirrhosis regressed from NASH Clinical Research Network stage 4 to stage 3 or lower in 33%. Median total weight loss was 23.9%, with an interquartile range of 18.0%–30.5%.

Regression was identified in 40% using modified Ishak staging versus 33% using NASH CRN staging. The Beijing classification detected regressive fibrosis features in 60%, alongside improvements in steatosis, inflammation and ballooning. The small, selected paired-biopsy cohort without a nonsurgical comparator cannot establish a treatment effect. The different histologic frameworks suggest that fibrosis remodeling may be more extensive than a single stage threshold captures.

KEY FINDING

Histologic cirrhosis regression occurred in a third of this selected surgical cohort over a median 6.2-year biopsy interval. The finding concerns compensated MASH cirrhosis and does not establish outcomes in decompensated disease.

Research Items (Sections A and B)

Ali Aminian, Awwab F. Hammad, Shaghayegh Sadeghmousavi et al. | Annals of Surgery, Nov. 3, 2026 | 10.1097/SLA.0000000000007251

A Cleveland Clinic retrospective cohort examined 4,929 adults with BMI ≥35 undergoing bypass or sleeve gastrectomy during 2018–2024. Among them, 61 had stopped semaglutide or tirzepatide because of intolerance, 207 had inadequate weight loss, and 4,661 had no prior exposure. Investigators estimated two-year surgical weight loss by procedure and diabetes status. The question was whether poor medication response also predicted poor results after surgery.

Among inadequate responders, adjusted two-year total weight loss was 32.7% after bypass versus 17.8% after sleeve, a 14.9-point difference (95% CI 13.1–16.7). In medication-intolerant patients without diabetes, corresponding procedure-specific estimates were 27.9% versus 20.1%. The small exposed subgroups and nonrandomized procedure selection limit causal interpretation. Medication response alone therefore appears insufficient to predict subsequent surgical weight loss.

KEY FINDING

Adjusted two-year weight loss among inadequate medication responders was 32.7% after bypass versus 17.8% after sleeve. Prior medication failure therefore coexisted with substantial subsequent surgical weight loss.

Multiple contributors | Science, Nov. 5, 2026 | Source ↗ | Introduction: Yevgeniya Nusinovich, Mattia Maroso, Joana Osório et al. | 10.1126/science.aen0869

Science's GLP-1 and Beyond collection brings obesity pharmacotherapy into a broader discussion of metabolic biology and clinical care. Reviews address adipose tissue remodeling, medication development and cognition. Perspectives examine addiction treatment and cancer risk, while a policy article considers global access. The collection treats these topics as distinct scientific questions rather than assuming that weight loss explains every possible effect.

The introductory essay places treatment tolerability and weight regain after withdrawal alongside the search for additional metabolic targets. It also considers unequal access as drug use expands across countries and patient groups. For obesity care, this connects biological mechanisms with the practical demands of sustained treatment. As a collection of reviews and perspectives, the issue provides no single trial population or pooled estimate of clinical benefit.

CONTEXT

GLP-1 and Beyond brings adipose biology, cognition and other potential treatment targets into one collection. Its focus includes the practical questions of tolerability, weight regain and unequal access.

Dashuai Li, Yaochi Cui, Zan Li | Obesity Reviews, Oct. 22, 2026 | 10.1111/obr.70250

A meta-analysis of 16 randomized trials assessed long-term exercise in adults with nonalcoholic fatty liver disease. Liver fat decreased with a standardized mean difference of −0.47 (95% CI −0.66 to −0.27). ALT also fell in the initial model, with a mean difference of −6.01 (95% CI −11.88 to −0.15; P=0.045), whereas AST did not change significantly. The analysis accounted for dependent effect sizes and shared comparator groups.

After small-sample cluster-robust correction, the liver-fat result remained significant but the ALT result did not. This distinction supports exercise for reducing hepatic fat without promising parallel enzyme improvement. An apparent favorable cumulative dose near 16 hours lay near the boundary of the available data, not an established prescription threshold. Few trials and multiple comparisons limit the exploratory dose-response and subgroup findings.

KEY FINDING

Liver fat fell with a standardized mean difference of −0.47, and the result remained significant after robust statistical correction. The initial ALT signal was less stable under the same correction.

Zewen Jiang, John M. Tayeri, Im-Hong Sun et al. | Nature, Oct. 28, 2026 | 10.1038/s41586-026-11181-4

A brief high-fat diet amplified experimentally induced skin inflammation in lean mice without requiring established obesity. After 1 or 10 weeks of high-fat feeding, ear thickening was approximately 2.1-fold and 2.3-fold greater than with low-fat feeding. A 4-day window around disease initiation was sufficient to reproduce the effect. Switching mice with obesity to a low-fat diet during that window blunted the inflammatory response despite persistent excess weight.

Neutrophil recruitment and NLRP3–IL-1 signaling helped establish pathogenic T-cell responses that outlasted the dietary exposure. Previously inflamed skin retained about 2.3-fold more resident memory CD4 cells, and inflammation intensified on rechallenge after recovery on a low-fat diet. Related lung experiments supported a similar mechanism; several authors disclosed pharmaceutical-company relationships outside this work. These mouse models do not establish that short dietary changes prevent inflammatory relapses in people.

CONTEXT

A four-day dietary window around inflammatory onset changed subsequent tissue responses in mice. The persistent immune imprint linked the initiating diet to later inflammation even after dietary reversal.

Andrew P. Gillikin, Emily P. Rabinovich, Abdelrahman A. Nimeri et al. | British Journal of Surgery, Nov. 3, 2026 | 10.1093/bjs/znag139

An overlap-weighted nationwide cohort compared 32,401 surgical patients with 347,457 adults starting obesity medications, all with obesity and type 2 diabetes. Median follow-up was 4.9 versus 4.3 years. Five-year major adverse cardiovascular event incidence was 6.1% after surgery versus 8.1% with medication (HR 0.78, 95% CI 0.73–0.84). Mortality was 2.1% versus 3.7% (HR 0.61, 95% CI 0.55–0.69).

Five-year nephropathy incidence was 4.5% after surgery versus 8.3% after medication initiation, while retinopathy incidence was 3.6% versus 7.4%. The direction of these associations was consistent with the cardiovascular and mortality findings. Residual confounding limits causal inference despite balanced measured covariates. This comparison describes routine treatment pathways rather than a trial against one specified drug regimen.

KEY FINDING

Five-year cardiovascular event incidence was 6.1% after surgery versus 8.1% after medication initiation. The accompanying mortality and microvascular associations point in the same direction.

Philip Conaghan, Thomas Schnitzer, David Hunter et al. | Arthritis & Rheumatology, ACR Convergence 2026 abstract 0871, Sep. 1, 2026 | Source ↗

TRIUMPH-4 randomized 445 adults with painful knee osteoarthritis and BMI ≥27 to weekly retatrutide 9 mg, 12 mg or placebo for 68 weeks. Under the efficacy estimand, WOMAC pain scores fell 4.48, 4.41 and 2.43 points, respectively, on a 0–10 scale; body weight fell 26.4%, 28.7% and 2.1% in the same order. Both doses outperformed placebo for both co-primary endpoints, with P<0.001 for each comparison.

Gastrointestinal events were usually mild to moderate and occurred mainly during dose escalation. Adverse events led to treatment discontinuation in 12.9%, 18.2% and 4.0% of the 9-mg, 12-mg and placebo groups; serious events occurred in 9.5%, 10.8% and 2.0%. Each retatrutide arm had one death, versus none with placebo, without causal attribution in the table. Presented at ACR Convergence 2026 with Lilly-associated authors, these findings are not yet peer-reviewed.

CONTEXT

Retatrutide reduced pain and body weight more than placebo over 68 weeks in adults with painful knee osteoarthritis. Treatment discontinuation and serious adverse events were more frequent in the active-treatment arms, so efficacy alone does not settle the benefit–risk assessment.

Yousef Mesaed Al-Shammari, Amna Jawad AlDorai, Rahaf AlAmirah et al. | Obesity Surgery, Nov. 5, 2026 | 10.1007/s11695-026-09003-7

A National Inpatient Sample analysis examined 284,230 adult bariatric hospitalizations during 2016–2022; 3.4% had documented chronic kidney disease. Crude in-hospital mortality was 0.3% without CKD versus 5.9% with stage 4 disease and 4.9% with dialysis-dependent end-stage renal disease. Relative to no CKD, adjusted mortality odds were higher for stage 4 (aOR 3.85, 95% CI 2.58–5.75) and dialysis dependence (aOR 7.34, 95% CI 5.33–10.12).

Stages 1–3 were not significantly associated with mortality after adjustment, despite crude mortality of 2.0% in stage 3 versus 0.3% without CKD. Stage 4 disease was also associated with new dialysis (aOR 16.47, 95% CI 9.19–29.51). Administrative coding, inpatient selection and residual confounding limit generalization to all bariatric patients. These findings distinguish advanced renal disease from earlier CKD rather than imply uniform surgical risk; the authors reported no funding.

KEY FINDING

Stage 4 CKD and dialysis dependence were associated with substantially greater in-hospital mortality. The stage-specific pattern is more informative than treating all CKD as one perioperative risk category.

D — Metabolic Marketplace

Eunhae Shin, Alice Chen | Health Affairs Scholar, Oct. 25, 2026 | 10.1093/haschl/qxag299 | USC Schaeffer, Nov. 6, 2026: Institutional report ↗

USC Schaeffer's report on Shin and Chen's formulary study describes scarce coverage for non-diabetes GLP-1 indications during 2024–2026. No standalone Part D plan listed Wegovy or Zepbound, versus coverage for 1%–2% of Medicare Advantage enrollees in any year. Among beneficiaries with coverage, 42% retained it from 2024 to 2025, compared with 16% from 2025 to 2026. No plan covered the drugs throughout all three years.

The distinction is between eligibility for a covered indication and availability on a plan's formulary, rather than the statutory exclusion of drugs used solely for weight loss. USC reports that plans dropping the drugs accounted for most coverage losses, rather than plan cancellations. Coverage was therefore fragile even for beneficiaries who initially had it. Formulary inclusion alone does not measure prescription approval, dispensing or sustained treatment.

KEY FINDING

Annual coverage reached only 1%–2% of Medicare Advantage enrollees, and continuity was uncommon. The findings describe a gap between additional drug indications and stable formulary access.

Centers for Medicare & Medicaid Services | CMS, Nov. 4, 2026 | Source ↗

CMS's final 2027 Physician Fee Schedule sets conversion factors of $32.95 for qualifying alternative-payment-model participants and $32.63 for other clinicians. These compare with $33.57 and $33.40 in 2026, decreases of 1.83% and 2.31%. The temporary 2.5% increase enacted for 2026 expires, outweighing statutory updates. The payment changes take effect January 1, 2027, according to the agency's November 4 fact sheet.

For separately billed same-day office E/M visits and zero-day global procedures, the highest-cost service retains 100% payment and the others receive 80%. The proposal would have paid those additional services at 50% and included 10- and 90-day global procedures. The final rule narrows both the size and scope of that reduction. Conversion-factor changes alone cannot determine a practice's revenue effect because service mix and relative-value changes also matter.

CONTEXT

The 2027 conversion factors fall 1.83% and 2.31% for the two clinician categories. The same-day reduction applies to zero-day global procedures, not the proposed 10- and 90-day categories.

Andel Co-op, Inc. | PR Newswire, Oct. 28, 2026 | Source ↗

Andel announced an October 28 collaboration with Novo that lets employers contribute toward Wegovy purchases outside traditional pharmacy benefits. The company describes access to injectable and oral formulations through its medication marketplace. Employers set their own contribution rather than purchasing a uniform insurance benefit. Andel coordinates prescription verification and delivery, while employees remain responsible for the remaining charge.

The arrangement separates an employer's financial contribution from the decision to include obesity medication in a pharmacy benefit. According to Andel, the program works alongside existing benefits and allows participants to keep their physicians. Its discount program is not insurance, so the contribution determines how much of the purchase price shifts away from the employee. The announcement provides no independent clinical or cost-effectiveness evaluation of this approach.

CONTEXT

Employer-selected contributions are the central feature of the Andel–Novo arrangement. They offer a payment route outside pharmacy benefits rather than equivalent insurance coverage.

Closing the gaps in knowledge...

Production Editor John D. Scott MD FACS | [email protected]

This issue's ballot: 6 of 11 board seats voted.
MBS Digest | November 10, 2026 | Vol. 2, Issue 18
For educational purposes only.